An open label, two-way crossover study to evaluate the absolute bioavailability of BnoX Trademark, a novel sublingual wafer formulation of buprenorphine, in healthy volunteers under fasted conditions.
Latest Information Update: 16 Jul 2019
At a glance
- Drugs Buprenorphine (Primary) ; Buprenorphine (Primary) ; Naltrexone
- Indications Pain
- Focus Pharmacokinetics
- Sponsors iX Biopharma
- 17 May 2017 Status changed from not yet recruiting to completed.
- 15 May 2017 Results published in the iX Biopharma media release.
- 05 Jan 2017 New trial record